The pharmaceutical landscape for obesity treatment has been irrevocably reshaped, as Novo Nordisk announced today that its Wegovy (semaglutide) 25 mg tablets have surpassed three million prescriptions in just over five months since its US launch. This unprecedented adoption rate positions the oral formulation as one of the strongest pharmaceutical launches by volume in US history, signaling a profound shift in how obesity is addressed and managed.
The sheer velocity of this market penetration is staggering, with approximately one Wegovy pill prescription being filled every five seconds. Launched in early January 2026, following its FDA approval on December 22, 2025, the Wegovy pill quickly reached its first million prescriptions within 12 weeks. An additional two million prescriptions were filled in the subsequent 10 weeks, culminating in today’s milestone. This rapid uptake is not merely a redirection of existing patients; over 80% of these new prescriptions are for individuals entirely new to GLP-1 therapy, indicating a significant expansion of the overall obesity treatment market rather than cannibalization.
For Novo Nordisk, the commercial success of the Wegovy pill is already translating into substantial revenue. The first quarter of 2026 saw oral Wegovy generate DKr 2.3 billion, approximately $360 million, underscoring the immense financial implications of this drug. For cash-paying patients, the monthly cost ranges from $149 for the starting 1.5mg dose to $299 for the highest doses, reflecting a premium pricing strategy that the market appears willing to bear.
Mike Doustdar, president and CEO of Novo Nordisk, emphasized the dual impact of the Wegovy pill. He stated that the oral formulation offers adults with obesity significant weight loss when combined with diet and exercise. Crucially, its FDA approval extends to lowering the risk of major cardiovascular events—such as death, heart attack, or stroke—in adults with obesity and known heart disease, a distinction that truly sets it apart in the therapeutic landscape. The convenience of an oral formulation, compared to injectables, is widely recognized as a pivotal factor driving its widespread adoption and empowering patients to embark on or sustain their weight loss journeys.
The clinical foundation for the Wegovy pill‘s approval is robust, rooted in the OASIS clinical trials and the landmark SELECT trial. Specifically, the OASIS 4 trial demonstrated an impressive mean weight loss of 13.6% at 64 weeks, with a remarkable one in three participants achieving 20% or greater weight loss. This efficacy is comparable to the established injectable Wegovy 2.4 mg, while maintaining a consistent safety and tolerability profile. Such compelling data provides healthcare providers with confidence in prescribing this new modality.
The global rollout of the Wegovy pill is now gaining momentum. The United Arab Emirates (UAE) became the first country outside the US to launch the Wegovy pill, following approval from the Emirates Drug Establishment earlier this week. Emil Kongshøj Larsen, executive vice president of International Operations at Novo Nordisk, indicated that future international launches in the latter half of 2026 will be strategically guided by local patient demand, the readiness of healthcare professionals, and the strength of existing healthcare and telehealth infrastructure. The UAE, he noted, demonstrated exceptional readiness in these critical areas. The drug is currently awaiting marketing approval from the European Medicines Agency (EMA) and other regulatory bodies, with UK approval anticipated in late 2026, signaling a broadening global footprint for this transformative treatment.
“The rapid adoption of the Wegovy pill isn’t just a commercial success; it’s a public health inflection point, demonstrating a clear demand for accessible, effective obesity treatments.”
This significant announcement coincides with Novo Nordisk’s prominent presence at the American Diabetes Association’s (ADA) 86th Scientific Sessions in New Orleans, Louisiana, running from June 5-8, 2026. The conference, a convergence point for over 12,000 global experts, serves as a crucial platform for unveiling breakthrough research in diabetes and obesity care. Novo Nordisk is presenting new clinical data, including various analyses of Wegovy in adults with obesity, aligning with key conference themes such as advances in obesity and metabolic health, cardiometabolic outcomes, and next-generation therapies. The timing of this milestone announcement amplifies its resonance within the medical community, reinforcing the drug’s scientific backing and market potential. Related trending articles delve into the broader implications for pharmaceutical innovation.
The Wegovy pill‘s swift ascent past the three million prescription mark underscores a fundamental shift in how obesity is perceived and treated. It moves beyond lifestyle modifications alone, offering a powerful pharmacological tool that is both highly effective and, critically, convenient. This success story has profound implications for investors tracking the pharmaceutical sector, healthcare providers seeking new solutions for a chronic disease, and millions of patients worldwide struggling with obesity and its associated health risks. The market has spoken definitively: the oral GLP-1 therapy is not just a new option; it is a game-changer.
